LABCORP HOLDINGS INC

Labcorp shares climb 1.91% to $329.93, backed by FDA partnership and BioReference acquisition, boosting lab services and drug‑safety research.

Labcorp shares rise modestly to $323.75, staying above its 200‑day MA amid mixed peer performance—stable valuation in a volatile healthcare market.

Labcorp’s Q4 dividend and planned Myriad Genetics acquisition signal a 12‑15% upside, blending steady returns with high‑growth precision diagnostics.